137 related articles for article (PubMed ID: 8703810)
1. Tucaresol increases oxygen affinity and reduces haemolysis in subjects with sickle cell anaemia.
Arya R; Rolan PE; Wootton R; Posner J; Bellingham AJ
Br J Haematol; 1996 Jun; 93(4):817-21. PubMed ID: 8703810
[TBL] [Abstract][Full Text] [Related]
2. The pharmacokinetics, tolerability and pharmacodynamics of tucaresol (589C80; 4[2-formyl-3-hydroxyphenoxymethyl] benzoic acid), a potential anti-sickling agent, following oral administration to healthy subjects.
Rolan PE; Parker JE; Gray SJ; Weatherley BC; Ingram J; Leavens W; Wootton R; Posner J
Br J Clin Pharmacol; 1993 Apr; 35(4):419-25. PubMed ID: 8485022
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological modification of oxygen affinity improves deformability of deoxygenated sickle erythrocytes: a possible therapeutic approach to sickle cell disease.
Keidan AJ; Sowter MC; Johnson CS; Marwah SS; Stuart J
Clin Sci (Lond); 1989 Apr; 76(4):357-62. PubMed ID: 2714049
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of tucaresol, an antisickling agent, in healthy volunteers.
Rolan PE; Mercer AJ; Wootton R; Posner J
Br J Clin Pharmacol; 1995 Apr; 39(4):375-80. PubMed ID: 7640143
[TBL] [Abstract][Full Text] [Related]
5. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease.
Oksenberg D; Dufu K; Patel MP; Chuang C; Li Z; Xu Q; Silva-Garcia A; Zhou C; Hutchaleelaha A; Patskovska L; Patskovsky Y; Almo SC; Sinha U; Metcalf BW; Archer DR
Br J Haematol; 2016 Oct; 175(1):141-53. PubMed ID: 27378309
[TBL] [Abstract][Full Text] [Related]
6. Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin.
Henry ER; Metaferia B; Li Q; Harper J; Best RB; Glass KE; Cellmer T; Dunkelberger EB; Conrey A; Thein SL; Bunn HF; Eaton WA
Blood; 2021 Sep; 138(13):1172-1181. PubMed ID: 34197597
[TBL] [Abstract][Full Text] [Related]
7. Effect of BW12C on oxygen affinity of haemoglobin in sickle-cell disease.
Keidan AJ; Franklin IM; White RD; Joy M; Huehns ER; Stuart J
Lancet; 1986 Apr; 1(8485):831-4. PubMed ID: 2870317
[TBL] [Abstract][Full Text] [Related]
8. Interactions of an Anti-Sickling Drug with Hemoglobin in Red Blood Cells from a Patient with Sickle Cell Anemia.
Strader MB; Liang H; Meng F; Harper J; Ostrowski DA; Henry ER; Shet AS; Eaton WA; Thein SL; Alayash AI
Bioconjug Chem; 2019 Mar; 30(3):568-571. PubMed ID: 30794381
[TBL] [Abstract][Full Text] [Related]
9. A Triazole Disulfide Compound Increases the Affinity of Hemoglobin for Oxygen and Reduces the Sickling of Human Sickle Cells.
Nakagawa A; Ferrari M; Schleifer G; Cooper MK; Liu C; Yu B; Berra L; Klings ES; Safo RS; Chen Q; Musayev FN; Safo MK; Abdulmalik O; Bloch DB; Zapol WM
Mol Pharm; 2018 May; 15(5):1954-1963. PubMed ID: 29634905
[TBL] [Abstract][Full Text] [Related]
10. New developments in anti-sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin in vivo?
Oder E; Safo MK; Abdulmalik O; Kato GJ
Br J Haematol; 2016 Oct; 175(1):24-30. PubMed ID: 27605087
[TBL] [Abstract][Full Text] [Related]
11. Identification of a small molecule that increases hemoglobin oxygen affinity and reduces SS erythrocyte sickling.
Nakagawa A; Lui FE; Wassaf D; Yefidoff-Freedman R; Casalena D; Palmer MA; Meadows J; Mozzarelli A; Ronda L; Abdulmalik O; Bloch KD; Safo MK; Zapol WM
ACS Chem Biol; 2014 Oct; 9(10):2318-25. PubMed ID: 25061917
[TBL] [Abstract][Full Text] [Related]
12. Substituted benzaldehydes (12C79 and 589C80) that stabilize oxyhaemoglobin also protect sickle cells against calcium-mediated dehydration.
Stone PC; Nash GB; Stuart J
Br J Haematol; 1992 Jul; 81(3):419-23. PubMed ID: 1390217
[TBL] [Abstract][Full Text] [Related]
13. GBT021601 improves red blood cell health and the pathophysiology of sickle cell disease in a murine model.
Dufu K; Alt C; Strutt S; Partridge J; Tang T; Siu V; Liao-Zou H; Rademacher P; Williams AT; Muller CR; Geng X; Pochron MP; Dang AN; Cabrales P; Li Z; Oksenberg D; Cathers BE
Br J Haematol; 2023 Jul; 202(1):173-183. PubMed ID: 36960712
[TBL] [Abstract][Full Text] [Related]
14. Treatment of sickle cell anemia with hydroxyurea and erythropoietin.
Goldberg MA; Brugnara C; Dover GJ; Schapira L; Charache S; Bunn HF
N Engl J Med; 1990 Aug; 323(6):366-72. PubMed ID: 1695325
[TBL] [Abstract][Full Text] [Related]
15. Increasing haemoglobin oxygen affinity to prevent sickling: abnormal haemoglobin variants as models.
Franklin IM; Huehns ER; Rosemeyer MA
Br J Haematol; 1986 Oct; 64(2):319-29. PubMed ID: 3778826
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulation induced by tucaresol in HIV infection: results of a 16 week pilot Phase I/II trial.
Gori A; Trabattoni D; Bandera A; Saresella M; Marchetti G; Gazzola L; Biasin M; Rhodes J; McDade H; Panebianco R; Galli M; Moroni M; Ferrante P; Thomas N; Franzetti F; Bray D; Clerici M
Antivir Ther; 2004 Aug; 9(4):603-14. PubMed ID: 15456092
[TBL] [Abstract][Full Text] [Related]
17. Substituted benzaldehydes designed to increase the oxygen affinity of human haemoglobin and inhibit the sickling of sickle erythrocytes.
Beddell CR; Goodford PJ; Kneen G; White RD; Wilkinson S; Wootton R
Br J Pharmacol; 1984 Jun; 82(2):397-407. PubMed ID: 6733364
[TBL] [Abstract][Full Text] [Related]
18. Voxelotor does not inhibit sickle hemoglobin fiber formation upon complete deoxygenation.
Worth EH; Fugate MK; Ferrone FA
Biophys J; 2023 Jul; 122(13):2782-2790. PubMed ID: 37270670
[TBL] [Abstract][Full Text] [Related]
19. The effect of urea on sickling.
May A; Huehns ER
Br J Haematol; 1975 May; 30(1):21-9. PubMed ID: 1191570
[TBL] [Abstract][Full Text] [Related]
20. A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease.
Howard J; Hemmaway CJ; Telfer P; Layton DM; Porter J; Awogbade M; Mant T; Gretler DD; Dufu K; Hutchaleelaha A; Patel M; Siu V; Dixon S; Landsman N; Tonda M; Lehrer-Graiwer J
Blood; 2019 Apr; 133(17):1865-1875. PubMed ID: 30655275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
